Cambridge Healthtech Institute’s 19th Annual

Oligonucleotide and Peptide CMC and Manufacturing

Advancing Process Control, Product Quality, and Scalable Manufacturing

June 15-16, 2027

Growing demand for oligonucleotide and peptide therapeutics is driving innovation in manufacturing processes that balance product quality, scalability, cost, and sustainability. The Oligonucleotide and Peptide CMC and Manufacturing conference brings together experts in bioprocessing, process chemistry, analytical sciences, and CMC to explore practical solutions for the development and manufacturing of ASOs, siRNAs, gRNAs, peptide therapeutics, conjugates, and emerging modalities. Sessions will address persistent manufacturing challenges, including synthesis efficiency, purification, endotoxin removal, impurity control, analytical characterization, phase-appropriate CMC strategies, and scale-up. The program will also examine advances in enzymatic and hybrid manufacturing, novel biological production platforms for peptides, process intensification, formulation, and technology transfer, with an emphasis on data-driven case studies and strategies that improve process robustness, reduce manufacturing costs and waste, and support consistent product quality from development through commercial production.

Coverage will include, but is not limited to:

  • Oligonucleotide Purification, Impurity Control, and Analytical Characterization
    • Improving endotoxin removal, purification efficiency, and product recovery
    • Identifying and controlling process-related impurities, degradants, and residual starting materials
    • Advancing LC-MS, high-resolution mass spectrometry, chromatography, and sequencing for impurity profiling and product characterization
    • Establishing meaningful specifications and linking process parameters to product quality
    • Overcoming purification challenges associated with sequence length and chemical modifications
  • Phase-Appropriate CMC Strategies and Regulatory Readiness
    • Developing robust CMC frameworks from early clinical development through commercial manufacturing
    • Defining critical quality attributes and scientifically justified control strategies
    • Addressing comparability, process changes, and lifecycle management
    • Aligning analytical development, process understanding, and regulatory expectations
  • Scaling Complex Oligonucleotides and Conjugates
    • Optimizing solid-phase synthesis and evaluating liquid-phase, enzymatic, and hybrid manufacturing approaches
    • Overcoming process bottlenecks in chemically modified ASOs, siRNAs, and other complex oligonucleotides
    • Improving conjugation efficiency, product homogeneity, and purification of oligonucleotide conjugates
    • Strengthening process robustness, technology transfer, and manufacturing readiness
  • Peptide Process Innovation and Manufacturing at Scale
    • Scaling solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid methods to improve yield and throughput
    • Exploring microbial, recombinant, and emerging biological production platforms for therapeutic peptides
    • Evaluating novel manufacturing technologies, including expanded genetic code approaches
    • Addressing purification, capacity, and cost challenges in GLP-1 and other complex peptide therapeutics
  • Peptide Formulation, Stability, and Developability
    • Addressing solubility, aggregation, and stability challenges in complex and long-acting peptide formulations
    • Understanding peptide–peptide interactions and compatibility in coformulations
    • Advancing formulation technologies, injectables, and extended-release delivery
    • Integrating analytical and stability strategies to maintain product quality and shelf life
  • Process Intensification, Sustainability, and Commercial Scale-Up
    • Reducing solvent consumption, waste generation, and manufacturing costs without compromising product quality
    • Applying automation, digital tools, and continuous processing to improve process efficiency and reproducibility
    • Translating facility design, capacity planning, and equipment selection into practical manufacturing advantages
    • Strengthening technology transfer and supply-chain readiness to support reliable GMP production
  • Cross-Modal Manufacturing Challenges and Emerging Opportunities
    • Applying lessons from oligonucleotide–peptide conjugates and other increasingly complex therapeutic modalities
    • Integrating drug substance, analytical, and drug product development to improve manufacturing consistency
    • Sharing practical case studies on resolving process bottlenecks, improving yield and recovery, and scaling innovative production platforms

The deadline for priority consideration is November 20, 2026.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation:


For more details on the conference, please contact:
Samina Taherbhoy
Conference Director
Cambridge Healthtech Institute
Email: [email protected]

For sponsorship information, please contact:

Companies A-K
Phillip Zakim-Yacouby
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-247-1815
Email: [email protected]

Companies L-Z
Aimee Croke
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-292-0777
Email: [email protected]